Publications

Nature genetics

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.

01-06-2022

American journal of human genetics

Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.

05-11-2020

Nature communications

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.

16-01-2020

Breast cancer research : BCR

Prediction and clinical utility of a contralateral breast cancer risk model.

17-12-2019

The American journal of surgical pathology

Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.

01-11-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study.

01-08-2018

Breast cancer research and treatment

Cardiovascular disease risk after breast cancer treatment in patients with a BRCA1/2 pathogenic variant.

31-10-2024

Breast (Edinburgh, Scotland)

The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy.

28-10-2024

BMJ open

Cohort profile: a nationwide study in Dutch CHEK2 c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands - Hebon-CHEK2.

09-10-2024

Journal of cancer survivorship : research and practice

Moderators of exercise effects on self-reported cognitive functioning in cancer survivors: an individual participant data meta-analysis.

01-10-2024

Nature medicine

Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial.

01-10-2024

American journal of human genetics

Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset.

05-09-2024

medRxiv : the preprint server for health sciences

Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification.

04-09-2024

Genetics in medicine : official journal of the American College of Medical Genetics

Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families.

01-09-2024

Gynecologic oncology

Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.

01-08-2024

Nature genetics

Publisher Correction: Understanding the genetic complexity of puberty timing across the allele frequency spectrum.

01-08-2024

Journal of medical genetics

Validation of the BOADICEA model in a prospective cohort of BRCA1/2 pathogenic variant carriers.

19-07-2024

Journal of the National Cancer Institute

Risk factors for breast cancer subtypes by race and ethnicity: A scoping review.

17-07-2024

Nature genetics

Understanding the genetic complexity of puberty timing across the allele frequency spectrum.

01-07-2024

Cancer discovery

Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care Globally.

01-07-2024

Bioinformatics advances

Assessing the validity of driver gene identification tools for targeted genome sequencing data.

29-05-2024

medRxiv : the preprint server for health sciences

Risk factors for breast cancer subtypes by race and ethnicity: A scoping review of the literature.

19-03-2024

ESMO open

Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.

01-03-2024

medRxiv : the preprint server for health sciences

Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction.

13-02-2024

Scandinavian journal of medicine & science in sports

Dropout from exercise trials among cancer survivors-An individual patient data meta-analysis from the POLARIS study.

01-02-2024

Breast (Edinburgh, Scotland)

The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families.

01-02-2024

BMJ (Clinical research ed.)

Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ.

24-01-2024

BMC medicine

Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.

09-01-2024

European journal of cancer (Oxford, England : 1990)

External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.

01-12-2023

Journal of medical genetics

Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel.

27-11-2023

Journal of the National Cancer Institute

Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation.

08-11-2023

Nature genetics

Author Correction: Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.

01-11-2023

BMJ (Clinical research ed.)

Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.

30-10-2023

Journal of empirical research on human research ethics : JERHRE

Health Research with Data in a Time of Privacy: Which Information do Patients Want?

01-10-2023

Breast (Edinburgh, Scotland)

Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: A survey within the MINDACT cohort.

01-10-2023

Cancers

DCIS and LCIS: Are the Risk Factors for Developing In Situ Breast Cancer Different?

02-09-2023

Nature genetics

Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.

01-09-2023

Breast cancer research : BCR

A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry.

09-08-2023

Cancer medicine

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.

01-08-2023

Nature communications

Obesity-associated changes in molecular biology of primary breast cancer.

21-07-2023

Cancers

Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases.

23-06-2023

Breast cancer research : BCR

Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium.

20-06-2023

medRxiv : the preprint server for health sciences

Understanding the genetic complexity of puberty timing across the allele frequency spectrum.

20-06-2023

NPJ breast cancer

PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants.

12-05-2023

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors.

10-05-2023

Breast cancer research : BCR

Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.

09-05-2023

European journal of human genetics : EJHG

FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women.

01-05-2023

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival.

01-04-2023

Journal of medical genetics

Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases.

01-04-2023

American journal of human genetics

The impact of coding germline variants on contralateral breast cancer risk and survival.

02-03-2023

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.

Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.

Prediction and clinical utility of a contralateral breast cancer risk model.

Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.

Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study.

Cardiovascular disease risk after breast cancer treatment in patients with a BRCA1/2 pathogenic variant.

The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy.

Cohort profile: a nationwide study in Dutch CHEK2 c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands - Hebon-CHEK2.

Moderators of exercise effects on self-reported cognitive functioning in cancer survivors: an individual participant data meta-analysis.

Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial.

Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset.

Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification.

Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families.

Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.

Publisher Correction: Understanding the genetic complexity of puberty timing across the allele frequency spectrum.

Validation of the BOADICEA model in a prospective cohort of BRCA1/2 pathogenic variant carriers.

Risk factors for breast cancer subtypes by race and ethnicity: A scoping review.

Understanding the genetic complexity of puberty timing across the allele frequency spectrum.

Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care Globally.

Assessing the validity of driver gene identification tools for targeted genome sequencing data.

Risk factors for breast cancer subtypes by race and ethnicity: A scoping review of the literature.

Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.

Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction.

Dropout from exercise trials among cancer survivors-An individual patient data meta-analysis from the POLARIS study.

The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families.

Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ.

Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.

External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.

Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel.

Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation.

Author Correction: Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.

Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.

Health Research with Data in a Time of Privacy: Which Information do Patients Want?

Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: A survey within the MINDACT cohort.

DCIS and LCIS: Are the Risk Factors for Developing In Situ Breast Cancer Different?

Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.

A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry.

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.

Obesity-associated changes in molecular biology of primary breast cancer.

Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases.

Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium.

Understanding the genetic complexity of puberty timing across the allele frequency spectrum.

PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants.

High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors.

Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.

FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women.

Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival.

Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases.

The impact of coding germline variants on contralateral breast cancer risk and survival.

This site uses cookies